Part I | Chapter 6 114 significant difference in GU toxicity at 6 and 12 months FU compared to baseline was observed (Table 2). For the non-ADT patients, a significant increase in ED toxicity from 24.3% grade 1, 13.5% grade 2, and 2.2% grade 3 ED at baseline to 28.8% grade 1, 21.2% grade 2, and 3.8% grade 3 ED at 12 months FU (p = 0.034) was observed. Characteristic Total group (n = 425) Age in years, median (range) 70 (51-85) cT-stage, n (%) cT1 162 (39.2) cT2 230 (55.7) cT3 21 (5.1) Missing (n) 12 ISUP grade, n (%) 1 90 (21.2) 2 261 (61.6) 3 69 (16.3) 4 4 (0.9) Missing (n) 14 PSA in ng/mL, n (%) < 10.0 ng/mL 291 (68.8) 10.0-20.0 ng/mL 120 (28.4) > 20.0 ng/mL 12 (2.8) Missing (n) 2 NCCN risk classification, n (%) Low 47 (11.4) Intermediate 337 (82.0) High 27 (6.6) Missing (n) 14 ADT, n (%) No 347 (81.6) Yes 78 (18.4) Missing (n) 0 Table 1 – Baseline characteristics. Legend: cT-stage = Clinical tumour stage. ISUP = International Society of Urological Pathology. PSA = Prostate-specific antigen. NCCN = National Comprehensive Cancer Network. ADT = Androgen deprivation therapy.
RkJQdWJsaXNoZXIy MTk4NDMw